Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.33 Million USD | -1011.02% |
| 2022 | 432.67 Thousand USD | 104.13% |
| 2021 | -10.48 Million USD | -22.59% |
| 2020 | -8.55 Million USD | 4.27% |
| 2019 | -8.93 Million USD | -45.41% |
| 2018 | -6.14 Million USD | -16.33% |
| 2017 | -5.28 Million USD | -33.85% |
| 2016 | -3.94 Million USD | 38.24% |
| 2015 | -6.38 Million USD | -800.9% |
| 2014 | -709.15 Thousand USD | 15.24% |
| 2013 | -836.61 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.36 Million USD | -35.33% |
| 2024 Q1 | -1.02 Million USD | -47.46% |
| 2023 Q3 | -772.91 Thousand USD | 23.67% |
| 2023 FY | -3.94 Million USD | -1011.02% |
| 2023 Q1 | -1.46 Million USD | -122.75% |
| 2023 Q2 | -1.01 Million USD | 30.83% |
| 2023 Q4 | -692.2 Thousand USD | 10.44% |
| 2022 Q2 | -1.71 Million USD | 34.06% |
| 2022 Q1 | -2.59 Million USD | 82.12% |
| 2022 FY | 432.67 Thousand USD | 104.13% |
| 2022 Q4 | 6.43 Million USD | 470.05% |
| 2022 Q3 | -1.73 Million USD | -1.63% |
| 2021 FY | -10.48 Million USD | -22.59% |
| 2021 Q2 | -4.54 Million USD | -70.09% |
| 2021 Q1 | -2.66 Million USD | 20.45% |
| 2021 Q3 | -3.01 Million USD | 33.59% |
| 2021 Q4 | -14.52 Million USD | -381.55% |
| 2020 Q1 | -2.33 Million USD | 42.84% |
| 2020 Q3 | -2.15 Million USD | -203.81% |
| 2020 Q4 | -3.35 Million USD | -55.95% |
| 2020 FY | -8.55 Million USD | 4.27% |
| 2020 Q2 | -708.22 Thousand USD | 69.68% |
| 2019 Q2 | -2.81 Million USD | -138.02% |
| 2019 Q3 | -2.41 Million USD | 14.21% |
| 2019 Q4 | -4.08 Million USD | -69.41% |
| 2019 FY | -8.93 Million USD | -45.41% |
| 2019 Q1 | -1.18 Million USD | 12.87% |
| 2018 Q4 | -1.35 Million USD | -18.88% |
| 2018 Q3 | -1.14 Million USD | 13.26% |
| 2018 Q2 | -1.31 Million USD | 43.63% |
| 2018 Q1 | -2.33 Million USD | -6.36% |
| 2018 FY | -6.14 Million USD | -16.33% |
| 2017 FY | -5.28 Million USD | -33.85% |
| 2017 Q4 | -2.19 Million USD | -38.64% |
| 2017 Q3 | -1.58 Million USD | -85.29% |
| 2017 Q2 | -853.73 Thousand USD | -30.82% |
| 2017 Q1 | -652.58 Thousand USD | 52.31% |
| 2016 Q1 | -722.81 Thousand USD | 33.7% |
| 2016 FY | -3.94 Million USD | 38.24% |
| 2016 Q4 | -1.36 Million USD | -58.87% |
| 2016 Q3 | -861.32 Thousand USD | 13.28% |
| 2016 Q2 | -993.18 Thousand USD | -37.4% |
| 2015 FY | -6.38 Million USD | -800.9% |
| 2015 Q3 | -2 Million USD | -31.95% |
| 2015 Q2 | -1.51 Million USD | 0.0% |
| 2015 Q1 | -1.51 Million USD | -738.44% |
| 2015 Q4 | -1.09 Million USD | 45.58% |
| 2014 Q4 | -181.08 Thousand USD | 0.0% |
| 2014 FY | -709.15 Thousand USD | 15.24% |
| 2013 FY | -836.61 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bright Green Corporation | -8.89 Million USD | 51.23% |
| BioQuest Corp. | -89.76 USD | -4830912.701% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 72.192% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 108.112% |
| GSRX Industries Inc. | - USD | Infinity% |
| High Sierra Technologies, Inc. | -238.36 Thousand USD | -1719.2% |
| Instadose Pharma Corp. | - USD | Infinity% |